313 related articles for article (PubMed ID: 24708745)
21. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
[TBL] [Abstract][Full Text] [Related]
23. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining.
Dessauvagie B; Thomas A; Thomas C; Robinson C; Combrink M; Budhavaram V; Kunjuraman B; Meehan K; Sterrett G; Harvey J
Pathology; 2019 Dec; 51(7):681-687. PubMed ID: 31630876
[TBL] [Abstract][Full Text] [Related]
24. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
25. Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging.
Hida AI; Omanovic D; Pedersen L; Oshiro Y; Ogura T; Nomura T; Kurebayashi J; Kanomata N; Moriya T
Histopathology; 2020 Sep; 77(3):471-480. PubMed ID: 32578891
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.
Ács B; Madaras L; Kovács KA; Micsik T; Tőkés AM; Győrffy B; Kulka J; Szász AM
Pathol Oncol Res; 2018 Jan; 24(1):115-127. PubMed ID: 28401450
[TBL] [Abstract][Full Text] [Related]
27. Automated imaging analysis of Ki-67 immunohistochemistry on whole slide images of cell blocks from pancreatic neuroendocrine neoplasms.
Shaker N; Shen R; Limbach AL; Satturwar S; Kobalka P; Ahmadian S; Sun S; Chen W; Lujan G; Esnakula A; Parwani A; Li Z
J Am Soc Cytopathol; 2024; 13(3):205-212. PubMed ID: 38433072
[TBL] [Abstract][Full Text] [Related]
28. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of digital and visual methods for Ki-67 assessment in invasive breast carcinomas].
Kushnarev VA; Artemyeva ES; Kudaybergenova AG
Arkh Patol; 2018; 80(2):38-42. PubMed ID: 29697670
[TBL] [Abstract][Full Text] [Related]
30. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
[TBL] [Abstract][Full Text] [Related]
31. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma.
Feng M; Deng Y; Yang L; Jing Q; Zhang Z; Xu L; Wei X; Zhou Y; Wu D; Xiang F; Wang Y; Bao J; Bu H
Diagn Pathol; 2020 May; 15(1):65. PubMed ID: 32471471
[TBL] [Abstract][Full Text] [Related]
32. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
33. Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer.
Maeda I; Abe K; Koizumi H; Nakajima C; Tajima S; Aoki H; Tsuchiya J; Tsuchiya S; Tsuchiya K; Shimo A; Tsugawa K; Ueno T; Tatsunami S; Takagi M
Breast Cancer; 2016 Sep; 23(5):745-51. PubMed ID: 26271611
[TBL] [Abstract][Full Text] [Related]
34. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
35. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
Cserni G; Vörös A; Liepniece-Karele I; Bianchi S; Vezzosi V; Grabau D; Sapino A; Castellano I; Regitnig P; Foschini MP; Zolota V; Varga Z; Figueiredo P; Decker T; Focke C; Kulka J; Kaya H; Reiner-Concin A; Amendoeira I; Callagy G; Caffrey E; Wesseling J; Wells C
Breast; 2014 Jun; 23(3):259-63. PubMed ID: 24613255
[TBL] [Abstract][Full Text] [Related]
36. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.
Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G
Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507
[TBL] [Abstract][Full Text] [Related]
37. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Acs B; Leung SCY; Kidwell KM; Arun I; Augulis R; Badve SS; Bai Y; Bane AL; Bartlett JMS; Bayani J; Bigras G; Blank A; Buikema H; Chang MC; Dietz RL; Dodson A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hartman J; Kos Z; Lænkholm AV; Laurinavicius A; Levenson RM; Mahboubi-Ardakani R; Mastropasqua MG; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Quintayo MA; Rau TT; Reinhard S; Robertson S; Salgado R; Sugie T; van der Vegt B; Viale G; Zabaglo LA; Hayes DF; Dowsett M; Nielsen TO; Rimm DL;
Mod Pathol; 2022 Oct; 35(10):1362-1369. PubMed ID: 35729220
[TBL] [Abstract][Full Text] [Related]
38. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
39. Automated characterization and counting of Ki-67 protein for breast cancer prognosis: A quantitative immunohistochemistry approach.
Mungle T; Tewary S; Arun I; Basak B; Agarwal S; Ahmed R; Chatterjee S; Maity AK; Chakraborty C
Comput Methods Programs Biomed; 2017 Feb; 139():149-161. PubMed ID: 28187885
[TBL] [Abstract][Full Text] [Related]
40. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
